Karo Bio Extends Collaboration with Pfizer
News Jun 27, 2013
Pfizer will continue to provide full funding for the research costs.
The collaboration that started in December 2011, aims to discover and develop novel small molecule RORgamma modulators for the treatment of autoimmune diseases. Pfizer is responsible for all research costs of the project. Karo Bio is eligible to receive over $200 million in milestone payments in addition to any royalty fees.
“We are pleased that Pfizer has chosen to extend our partnership. The decision illustrates the potential of the science behind RORgamma and its application to the treatment of autoimmune diseases. It also reconfirms the potential of Karo Bio’s technology and expertise in the development of drugs targeting nuclear receptors,” says CEO Per Bengtsson.
The nuclear hormone receptor RORgamma is a novel attractive target for the treatment of autoimmune diseases like rheumatoid arthritis, multiple sclerosis and psoriasis. RORgamma directly controls the production and secretion of the cytokine IL-17, a major contributor to inflammation. The receptor’s key role in driving disease pathology has been implicated in clinical trials using monoclonal antibodies that neutralize IL-17 activity. The agreement with Pfizer was entered into after Karo Bio discovered novel, potent, and specific RORgamma modulators.
Human Malaria Parasites Grown for the First Time in Dormant FormNews
One of the biggest obstacles to eradicating malaria is a dormant form of the parasite which is resistant to most antimalarial drugs and can reawaken years later, causing disease relapse. Researchers have shown they can grow the dormant parasite in engineered human liver tissue for several weeks, allowing them to closely study how the parasite becomes dormant, what vulnerabilities it may have, and how it springs back to life.READ MORE
Bacteria Produce More Substances Than Genetics PredictedNews
Tandem mass spectrometry has revealed that Streptomyces chartreusis, an antibiotic-producing bacterium, releases more metabolites into the surrounding medium than scientists assumed based on the analysis of the genome. They might include molecules that are of interest as potential pharmaceutical agents.READ MORE
Gut Bacteria Latest Ally in Fight Against SepsisNews
Sepsis occurs when the body's response to the spread of bacteria or toxins to the bloodstream damages tissues and organs. The fight against sepsis could get a helping hand from a surprising source: gut bacteria. Researchers found that giving mice particular microbes increased blood levels of immunoglobulin A (IgA) antibodies, which protected against the kind of widespread bacterial invasion that leads to sepsis.READ MORE